In the past week, CGTX stock has gone up by 22.57%, with a monthly gain of 40.34% and a quarterly plunge of -2.81%. The volatility ratio for the week is 8.87%, and the volatility levels for the last 30 days are 12.28% for Cognition Therapeutics Inc The simple moving average for the past 20 days is 16.47% for CGTX’s stock, with a -58.91% simple moving average for the past 200 days.
Is It Worth Investing in Cognition Therapeutics Inc (NASDAQ: CGTX) Right Now?
Company’s 36-month beta value is 1.37.Analysts have differing opinions on the stock, with 2 analysts rating it as a “buy,” 1 as “overweight,” 1 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for CGTX is 33.80M, and currently, short sellers hold a 2.41% ratio of that floaft. The average trading volume of CGTX on November 13, 2024 was 538.63K shares.
CGTX) stock’s latest price update
Cognition Therapeutics Inc (NASDAQ: CGTX)’s stock price has soared by 18.00 in relation to previous closing price of 0.51. Nevertheless, the company has seen a gain of 22.57% in its stock price over the last five trading days. globenewswire.com reported 2024-11-12 that PURCHASE, N.Y., Nov. 12, 2024 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that President and CEO Lisa Ricciardi will present live at the virtual Zacks SCR Life Sciences Investor Forum on November 14, 2024. The Company’s presentation will focus primarily on the results from the successful Phase 2 ‘SHINE’ study of CT1812 in mild-to-moderate Alzheimer’s disease. In addition, Ms. Ricciardi will provide an overview of the Company’s ongoing clinical programs, including the Phase 2 ‘SHIMMER’ study of CT1812 in dementia with Lewy bodies. Topline results from the ‘SHIMMER’ study are expected by year-end 2024.
Analysts’ Opinion of CGTX
Oppenheimer, on the other hand, stated in their research note that they expect to see CGTX reach a price target of $22. The rating they have provided for CGTX stocks is “Outperform” according to the report published on November 03rd, 2021.
B. Riley Securities gave a rating of “Buy” to CGTX, setting the target price at $27 in the report published on November 03rd of the previous year.
CGTX Trading at 17.71% from the 50-Day Moving Average
After a stumble in the market that brought CGTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -79.72% of loss for the given period.
Volatility was left at 12.28%, however, over the last 30 days, the volatility rate increased by 8.87%, as shares surge +42.14% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -5.62% lower at present.
During the last 5 trading sessions, CGTX rose by +22.57%, which changed the moving average for the period of 200-days by -74.54% in comparison to the 20-day moving average, which settled at $0.5137. In addition, Cognition Therapeutics Inc saw -67.65% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CGTX starting from Ricciardi Lisa, who purchase 5,700 shares at the price of $1.75 back on Mar 14 ’24. After this action, Ricciardi Lisa now owns 291,345 shares of Cognition Therapeutics Inc, valued at $9,975 using the latest closing price.
Stock Fundamentals for CGTX
Current profitability levels for the company are sitting at:
- -157.83 for the present operating margin
- 0.31 for the gross margin
The net margin for Cognition Therapeutics Inc stands at -83.55. The total capital return value is set at -2.5. Equity return is now at value -108.31, with -79.36 for asset returns.
Based on Cognition Therapeutics Inc (CGTX), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -36.63. The debt to equity ratio resting at 0.03. The interest coverage ratio of the stock is -2096.93.
Currently, EBITDA for the company is -50.63 million with net debt to EBITDA at 0.55. When we switch over and look at the enterprise to sales, we see a ratio of -10.47. The receivables turnover for the company is 0.12for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.07.
Conclusion
In a nutshell, Cognition Therapeutics Inc (CGTX) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
